Objective: Sorafenib has limited survival benefits with lower tumor response rates in hepatocellular carcinoma (HCC). Many researchers have attempted to identify predictors for sorafenib. In this study, we compared the role of lymphocyte/monocyte ratio (LMR), neutrophil/monocyte ratio (NMR), platelet/neutrophil ratio (PNR), systemic inflammation response index (SIRI) and systemic immune inflammation (SII) in patients with HCC received sorafenib treatment.
Materials and Methods: In this study, we retrospectively enrolled 80 patients who used Sorafenib in advanced stage HCC between January 2011 and December 2018. Baseline neutrophil, lymphocyte, monocyte and platelet counts were recorded. Cut-off points of LMR, NMR, PNR, SIRI and SII were calculated by the receiver operating characteristic (ROC) curve analysis. Overall survival (OS) and progression-free survival (PFS) were demonstrated by Kaplan-Meier analysis, and the log-rank test was used for comparing the curves
Results: Median OS was 29 weeks (95% CI 20.41–37.58), and PFS was 16 weeks (95% CI: 12.04–19.95). We found that only low SIRI value was associated with increased survival. OS were 19 weeks for SIRI ≥2.2 and 38 weeks (95% CI: 30.96–45.03 for patients with SIRI <2.2 (p=0.005). PFS was 12 weeks for SIRI ≥2.2 and 20 weeks for SIRI <2.2 (p=0.098). The life expectancy of patients with SIRI values less than 2.2 was 2.02 times higher than the other group.
Conclusion: To our knowledge, NMR and PNR indexes were evaluated for the first time in our study in HCC patients. Low SIRI value was related to increased survival in patients receiving sorafenib with HCC.